Impact of H63D mutations, magnetic resonance and metabolic syndrome among outpatient referrals for elevated serum ferritin in the Basque Country.

Castiella A, Zapata E, Zubiaurre L, Alustiza JM, De Juan,MD, Iribarren A, Emparanza JI, Otazua P.

Ann. Hepatol. 2015; 14: 333-339. FI: 2.065 (Q3).

MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.

Erice O, Smith MP, White R, Goicoechea I, Barriuso J, Jones C, Margison GP, Acosta JC, Wellbrock C, Arozarena I.

Mol. Cancer Ther. 2015; 14: 1236-1246. FI: 5.683 (Q1).

Methods for extracellular vesicles isolation in a hospital setting.

Saenz-Cuesta M, Arbelaiz A, Oregi A, Irizar H, Osorio-Querejeta I, Munoz-Culla M, Banales JM, Falcon-Perez JM, Olascoaga J, Otaegui D.

Front. Immunol. 2015; 6. FI: 5.695 (Q1).

Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain.

Turnes J, Diaz R, Hernandez-Guerra M, Gomez M, Castells L, Bustamante J, Espinosa, MD,Fernandez-Castroagudin J, Serrano T, Rendon P, Andrade R, Salgado M, Arenas J, Vergara M, Sala M, Polo BA, Granizo IM, Gonzalvez ML, Viudez A.

Gastroenterol. Hepatol. 2015; 38: 263-273. FI: 0.838 (Q4).

Measurement of Liver Iron Concentration by MRI Is Reproducible.

Alustiza JM, Emparanza JI, Castiella A, Casado A, Garrido A, Aldazabal P, San Vicente M, Garcia N, Asensio AB, Banales J, Salvador E, Moyua A, Arozena X, Zarco M, Jauregui L, Vicente O.

Biomed Res. Int. 2015; 2015: 294024-0. FI: 1.579 (Q3).

Post-translational Regulation of the Type III Inositol 1,4,5-Trisphosphate Receptor by miRNA-506.

Ananthanarayanan M, Banales JM, Guerra MT, Spirli C, Munoz-Garrido P, Mitchell-Richards K, Tafur D, Saez E, Nathanson MH.

J. Biol. Chem. 2015; 290: 184-196. FI: 4.573 (Q1).

Gallbladder metastasis from renal cell carcinoma, an extremely rare neoplastic dissemination location.

Zevallos JC, Lizarazu A, Guisasola E, Medrano MA, Jimenez R.

Cir. Espan. 2014; 92: 295-296. FI: 0.890 (Q3).

MicroRNAs and cholestatic liver diseases.

Marin JJG, Bujanda L, Banales JM.

Curr. Opin. Gastroenterol. 2014; 30: 303-309. FI: 3.664 (Q1).

Polycystic liver diseases: advanced insights into the molecular mechanisms.

Perugorria MJ, Masyuk TV, Marin JJ, Marzioni M, Bujanda L, LaRusso NF, Banales JM.

NAT REV GASTRO HEPAT. 2014; 11: 750-761. FI: 10.807 (Q1).

Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.

Castiella A, Zapata E, Lucena MI, Andrade RJ.

World J Hepatol. 2014; 6: 160-168. FI: 0.000 (Q0).

Mucinous cystic neoplasm of the gallbladder obstructing the common bile duct, a rare entity with a new name.

Zevallos Quiroz JC, Jimenez Agueero R, Garmendi Irizar M, Ruiz Montesinos I, Comba JW.

Cir. Espan. 2014; 92: 567-569. FI: 0.890 (Q3).

Polycystic liver in the adult (PLA) in Spain: Analysis of a structured survey analysing the experience and attitude of gastroenterologists in Spain.

Ampuero J, Banales JM, Soriano G, Crespo J, Luis Olcoz J, Diago M, Calleja JL, Romero-Gomez M.

Rev Esp Enferm Dig. 2014; 106: 263-275. FI: 1.317 (Q4).

Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish Hepatotoxicity Registry.

Perdices EV, Medina-Caliz I, Hernando S, Ortega A, Martin-Ocana F, Navarro JM, Pelaez G, Castiella A, Hallal H, Romero-Gomez M, Gonzalez-Jimenez A, Robles-Diaz M, Lucena MI, Andrade RJ, Registro Espanol Hepatotoxicidad.

Rev Esp Enferm Dig. 2014; 106: 246-254. FI: 1.317 (Q4).

Chronicity in idiosyncratic drug-induced liver injury (DILI): Causative drugs and risk factors.

Robles-Diaz M, Medina-Caliz I, Garcia-Munoz B, Stephens C, Gonzalez-Jimenez A, Garcia-Cortes M, Ortega-Alonso A, Hidalgo R, Fernandez MC, Romero-Gomez M, Calle-Sanz R, Fombuena B, Navarro JM, Hallal H, Barriocanal AM, Montane E, Blanco S, Castiella A, Zapata EM, Jimenez-Perez M, Moreno-Planas JM, Soriano G, Guarner C, Roman EM, Primo J, Aldea A, Prieto M, Andrade RJ, Lucena IM.

Basic Clin. Pharmacol. Toxicol. 2014; 115: 15-0. FI: 2.294 (Q2).